Literature DB >> 18090386

Antiretroviral drugs and liver injury.

Vincent Soriano, Massimo Puoti, Pilar Garcia-Gascó, Juergen K Rockstroh, Yves Benhamou, Pablo Barreiro, Barbara McGovern.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18090386     DOI： 10.1097/QAD.0b013e3282f0e2fd

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  46 in total

Review 1.  Indian National Association for Study of the Liver (INASL) Guidance for Antiviral Therapy Against HCV Infection in 2015.

Authors:  Pankaj Puri; Anil C Anand; Vivek A Saraswat; Subrat K Acharya; Radha K Dhiman; Shiv K Sarin; Shivaram P Singh; Yogesh K Chawla; Rakesh Aggarwal; Deepak Amarapurkar; Anil Arora; Vinod K Dixit; Ajit Sood; Samir Shah; Ajay Duseja; Dharmesh Kapoor; Kaushal Madan; Gaurav Pande; Aabha Nagral; Premashis Kar; Abraham Koshy; Amarender S Puri; C E Eapen; Sandeep Thareja
Journal:  J Clin Exp Hepatol       Date:  2015-09-21

2.  Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study.

Authors:  Sebastiano Leone; Milensu Shanyinde; Alessandro Cozzi Lepri; Fiona C Lampe; Pietro Caramello; Andrea Costantini; Andrea Giacometti; Andrea De Luca; Antonella Cingolani; Francesca Ceccherini Silberstein; Massimo Puoti; Andrea Gori; Antonella d'Arminio Monforte
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-01-09       Impact factor: 3.267

3.  Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C.

Authors:  Christopher B Hurt; Sonia Napravnik; Richard D Moore; Joseph J Eron
Journal:  Antivir Ther       Date:  2014-01-23

4.  Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients.

Authors:  Joseph K Lim; Janet P Tate; Shawn L Fultz; Joseph L Goulet; Joseph Conigliaro; Kendall J Bryant; Adam J Gordon; Cynthia Gibert; David Rimland; Matthew Bidwell Goetz; Marina B Klein; David A Fiellin; Amy C Justice; Vincent Lo Re
Journal:  Clin Infect Dis       Date:  2014-02-25       Impact factor: 9.079

5.  Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.

Authors:  Vincent Lo Re; Bret Zeldow; Michael J Kallan; Janet P Tate; Dena M Carbonari; Sean Hennessy; Jay R Kostman; Joseph K Lim; Matthew Bidwell Goetz; Robert Gross; Amy C Justice; Jason A Roy
Journal:  Pharmacoepidemiol Drug Saf       Date:  2017-07-19       Impact factor: 2.890

6.  Hepatitis B Virus-HIV Coinfection: Forgotten but Not Gone.

Authors:  Narayan Dharel; Richard K Sterling
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-12

7.  Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis.

Authors:  Donna L White; Vlad Ratziu; Hashem B El-Serag
Journal:  J Hepatol       Date:  2008-08-21       Impact factor: 25.083

Review 8.  Emerging challenges in managing hepatitis B in HIV patients.

Authors:  Vincent Soriano; Pablo Labarga; Carmen de Mendoza; José M Peña; José V Fernández-Montero; Laura Benítez; Isabella Esposito; Pablo Barreiro
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

9.  Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients.

Authors:  Michelle DallaPiazza; Valerianna K Amorosa; Russell Localio; Jay R Kostman; Vincent Lo Re
Journal:  BMC Infect Dis       Date:  2010-05-13       Impact factor: 3.090

10.  Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.

Authors:  Jules B Tchatchueng Mbougua; Christian Laurent; Charles Kouanfack; Anke Bourgeois; Laura Ciaffi; Alexandra Calmy; Henri Gwet; Sinata Koulla-Shiro; Jacques Ducos; Eitel Mpoudi-Ngolé; Nicolas Molinari; Eric Delaporte
Journal:  BMC Public Health       Date:  2010-03-01       Impact factor: 3.295
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.